

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/045,596
	Filing Date	October 18, 2001
	First Named Inventor	Paul A. Price
	Group Art Unit	1617
	Examiner Name	Theodore J. Criares
Attorney Docket Number	407T-893910US	


RECEIVED
DEC 18 2002
TECH CENTER 1600/2000

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
§	1	5,196,409		Saari et al.	02/02/1993	
§	2	5,183,815		Breuer et al.	03/23/1993	
§	3	5,294,608		Lang et al.	03/15/1994	
§	4	5,395,826		D'Souza et al. NAUMANN	04/04/1995	
§	5	5,403,824		Tyler et al. D'SOUZA	04/25/1995	
§	6	5,403,829		Sugioka et al. LEHTINEN	06/27/1995	
§	7	5,409,911		Barnes et al. TYLER	04/09/1996	
§	8	5,428,181		Hayashi SUGIOKA	03/18/1997	
§	9	5,498,617		Kaas et al. NAUMANN	06/09/1998	
§	10	5,506,211		Kaas et al. BARNES	01/05/1999	
§	11	5,661,174		Yallampalli et al. HAYASHI	04/27/1999	
§	12	5,733,564		Fuh et al. LEHTINEN	08/31/1999	
§	13	5,763,611		Lehtinen KASS	03/31/1998	
§	14	5,856,314		Lehtinen et al. KASS	04/04/1995	
§	15	5,898,038		Naumann et al. YALLAMPALLI	03/12/1996	
§	16	5,945,412		Naumann et al. FUH	03/12/1996	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

Examiner Signature		Date Considered	9/24/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/045,596
	Filing Date	October 18, 2001
	First Named Inventor	Paul A. Price
	Group Art Unit	1617
	Examiner Name	Theodore J. Criares
	Attorney Docket Number	407T-893910US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	17	L. AHRENGART ET AL. (1986) "Prevention of Ectopic Bone Formation by Local Application of Ethane-1-hydroxy, 1-diphosphane (EHDP): An Experimental Study in Rabbits", JOR 4:18-26	✓
	18	ALATLI ET AL. (1996) "Root surface defects in rat molar induced by 1-dihydroxyethylidene-1, 1-bisphosphonate", Acta Odontologica Scandinavica 54: 59-65	✓
	19	V. N. ANTIC ET AL. (1996) "Effect of Bisphosphonates on the Increase in Bone Resorption Induced by a Low Calcium Diet", Calcified Tissue Institute 58:443-448	✓
	20	BAUMANN ET AL. (1978) "Biochemical and clinical effects of ethane-1-dihydroxy-, 1-diphosphonate in calcium nephrolithiasis" Clinical Science and Molecular Medicine 54: 509-516	✓
	21	BLOCK M.D. ET AL. (1998) "Association of Serum Phosphorus and Calcium X Phosphate Product With Mortality Risk in Chronic Hemodialysis Patients: A National Study Vol. 31: 4: 607-617	✓
	22	BLOMEN (1995) Bijvoet OLM et al. Bisphosphonate on Bones, Elsevier, Amsterdam 111-124	✓
	23	BRINER ET AL. (1971) "The control of dental calculus in experimental animals", Vol. 21: 1 : 61-73	✓
	24	CASEY ET AL.(1972) "Polyribosomes in Rat Liver Slices During Incubation in Vitro", Specialia 15:2	
	25	COATES ET AL. (1998) "Cutaneous Necrosis from Calcific Uremic Arteriolopathy", American Journal of Kidney Diseases, Vol. 32: 3: 384-391	
	26	COHEN ET AL. "Bisphosphonates and Tetracycline: Experimental Models for Their Evaluation in Calcium-Related Disorders", Pharmaceutical Research 15:4:606-613	
	27	DARE ET AL. (1993) "New Observations on the Etiology of Aortic Valve Disease: A Surgical Pathologic Study of 236 Cases of 1990", Human Pathology, Vol. 24 : 12: 1330-1338	
	28	DAOUD ET AL. (1987) " The Effect of Ethane-1-Hydroxy-1, 1-Diphosphonate (EHDP) on Necrosis of Atherosclerotic Lesions", Artherosclerosis 67: 41-48	

Examiner Signature		Date Considered	9/26/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




RECEIVED
DEC 18 2002
TECH CENTER 1600/2900

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/045,596
	Filing Date	October 18, 2001
	First Named Inventor	Paul A. Price
	Group Art Unit	1617
	Examiner Name	Theodore J. Criares
	Attorney Docket Number	407T-893910US

§	29	FINERMAN (1981) "Heterotopic Ossification Following Hip Replacement or Spinal Cord Injury. Two Clinical Studies with EHDP", Metab. Bone Dis. & Rel. Res. 4&5: 337-342	
§	30	FLEISCH ET AL. (1970) "The Inhibitory Effect of Phosphates on the Formation of Calcium Phosphate Crystals in Vitro and on Aortic and Kidney Calcification in Vivo", Europ. J. Clin. Invest. 1: 12-18	
§	31	FLEISCH (1997) "Bisphosphonates: Preclinical Aspects and Use in Osteoporosis", The Finnish Medical Society DUIDECIM, Ann Med. 29: 55-62	
§	32	FLEISCH (1998) "Bisphosphonates: Mechanisms of Action", Endocrine Reviews 19 (1): 80-100	
§	33	FLEISCH (1999) "Bisphosphonates: A New Class of Drugs in Diseases of Bone and Calcium Metabolism", Calcium in Drug Actions 21:441-466	
§	34	FLORA (1980) "Comparative Skeletal Effects of Two Diphosphonates in Dogs", Metab. Bone Dis. Et Rel. Vol. 2S 389-407	
§	35	GOLDSMITH (1997) "Vascular Calcification in Long-Term Haemodialysis Patients in a Single Unit: A Retrospective Analysis", Nephron 77: 37-43	
§	36	GOLOMB (1986) "Controlled Release of Diphosphonate to Inhibit Bioprosthetic Heart Valve Calcification: Dose-Response and Mechanistic Studies", Journal of Controlled Release 4:181-194	
§	37	HAFNER (1995) "Uremic Small-Artery Disease with Medical Calcification and Intimal Hyperplasia (so-called calciphylaxis): A complication of chronic renal failure and benefit from parathyroidectomy", Journal of the American Academy of Dermatology 33:954-962	
§	38	HOLLANDER ET AL. (1979) "Effects of Anticalcifying and Antifibrotic Drugs on Pre-Established Atherosclerosis in the Rabbit", Artherosclerosis 33: 111-123	
§	39	KING (1971) "Effect of Disodium Ethane-1-Hydroxy-1, 1-Disphosphonate on Bone Formation", Clin. Oth. & Rel. Res. 78:251-269	
§	40	KRAMSCH ET AL. (1978) "The Effect of Agents Interfering with Soft Tissue Calcification and Cell Proliferation on Calcific Fibrous-Fatty Plaques in Rabbits", Circulation Research 42(4):562-572	/
§	41	KRAMSCH (1981) "Atherosclerosis: Prevention by Agents Not Affecting Abnormal	/

Examiner Signature		Date Considered	9/26/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




RECEIVED
DEC 19 2002
TECH CENTER 1600/2900

Substitution for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/045,596
	Filing Date	October 18, 2001
	First Named Inventor	Paul A. Price
	Group Art Unit	1617
	Examiner Name	Theodore J. Criares
	Attorney Docket Number	407T-893910US

		Levels of Blood Lipids", Science Vol. 213: 1511-1512	
§	42	LARSSON (1974) "The Short-Term Effects of High Doses of Ethylene-1-Hydroxy-1, 1-Diphosphonate upon Early Dentin Formation", Calc. Tiss. Res. 16: 109-127	
§	43	LEVY ET AL. (No Date) "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate", Science 228: 190-192	
§	44	MORI ET AL. (1998) "Expression of Matrix Gla Protein (MGP) in an In Vitro Model of Vascular Calcification", FEBS Letters 443: 19-22	
§	45	OGAWA (1980) "NaF, SrCl ₂ , EHDP", Jpn. J. Oral Biol., 55: 199-226 - NO TRANSLATION	
§	46	PLASMANS (1978) "The Effect of Ethane-1-Hydroxy-1, 1-Diphosphonic Acid (EHDP) on Matrix Induced Ectopic Bone Formation", Clin. Orth. & Rel. Res. 132: 233-243	
§	47	PRICE (1998) "Warfarin Causes Rapid Calcification of the Elastic Lamellae in Rat Arteries and Heart Valves", Arterioscler Thromb Vasc. Biol. 18: 1400-1407	
§	48	REINER et al. (No Date) Diphosphonate Treatment in Myositis Ossificans Progressiva" (no publication)	
§	49	ROSENBLUM ET AL. (1975) "The Effect of Disodium Ethane-1-Hydroxy-1, 1-Diphosphonate (EHDP) On a Rabbit Model of Athero-Arteriosclerosis", Artherosclerosis 22:411-424	
§	50	ROSENBLUM (1977) "The Effects of Various Diphosphonates on a Rat Model of Cardiac Calciphylaxis", Calif. Tiss. Res. 23: 151-159	
§	51	SCHENK (1973) "Effect of Ethane-1-Hydroxy-1, 1-Diphosphonate (EHDP) and Dichloromethylene Diphosphonate (Cl ₂ MDP) on the Calcification and Resorption of Cartilage and Bone in the Tibial Epiphysis and Metaphysis of Rats", Calc. Tiss. Res. 11: 196-214	
§	52	SLOOFF (No Date) "The use of a Diphosphonate in Para-Articular Ossifications after Total Hip Replacement. A Clinical Study", Prothese Totale De Genou Guepar	
§	53	TAKEO (1989) "Functional Changes of Aorta with Massive Accumulation of Calcium", Athersclerosis 77: 175-181	
§	53	TAKEO (1991) "Alterations in Cardiac Function and Subcellular Membrane Activities after Hypervitaminosis D3", Molec. & Cellu. Biochem. 107: 169-183	
§	54	THOMAS ET AL. (1985) "Results of the Administration of Diphosphonate for the	
Examiner Signature			Date Considered 9/26/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
DEC 19 2002
TECH CENTER 1800/2800

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/045,596
	Filing Date	October 18, 2001
	First Named Inventor	Paul A. Price
	Group Art Unit	1617
	Examiner Name	Theodore J. Criares
	Attorney Docket Number	407T-893910US

		Prevention of Heterotopic Ossification after Total Hip Arthroplasty", Journ. Of Bone and Joint Surgery 3: 400-403	
§	55	YLITALO ET AL. (1994) "Effects of Clodronate(Dichloromethylene Bisphosphonate) on the Development of Experimental Atherosclerosis in Rabbits", J. Lab. Clin. Med. 123: 769-776	/
§	56	WEILE ET AL. (1990) "Effects of Single Doses of 1-Hydroxyethylidene-1, 1-Bisphosphonate on the Mineralizing Front of Rat Incisor Enamel: A Microradiographic and Scanning Electron Microscopic Study", Arch. Oral. Biol. 35(11) 857-867.	/
§	57	ZHU ET AL. (1994) "Effects of Etidronate and Lovastatin on the Regression of Atherosclerosis in Choletero-Fed Rabbits", Cardiology 85: 370-377	/

Examiner Signature		Date Considered	9/26/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.